Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Development of a novel tool for assessing coverage of implementation factors in health promotion program resources.

Bejarano CM, Snow K, Lane H, Calvert H, Hoppe K, Alfonsin N, Turner L, Carlson JA.

Prev Med Rep. 2019 May 30;15:100909. doi: 10.1016/j.pmedr.2019.100909. eCollection 2019 Sep. No abstract available.

2.

The Academic, Behavioral, and Health Influence of Summer Child Nutrition Programs: A Narrative Review and Proposed Research and Policy Agenda.

Turner L, Calvert HG.

J Acad Nutr Diet. 2019 Jun;119(6):972-983. doi: 10.1016/j.jand.2019.02.006. Epub 2019 Apr 9.

PMID:
30979634
3.

An evaluation of the coverage of theoretically based implementation factors in disseminated classroom physical activity programs.

Calvert HG, Lane HG, Bejarano CM, Snow K, Hoppe K, Alfonsin N, Turner L, Carlson JA.

Transl Behav Med. 2018 Dec 26. doi: 10.1093/tbm/iby134. [Epub ahead of print]

PMID:
30590851
4.

Prevalence and Types of School-Based Out-of-School Time Programs at Elementary Schools and Implications for Student Nutrition and Physical Activity.

Sliwa SA, Calvert HG, Williams HP, Turner L.

J Sch Health. 2019 Jan;89(1):48-58. doi: 10.1111/josh.12710.

5.

A Vaginal Angiomyofibroblastoma as a Rare Cause of a Prolapsing Vaginal Mass: A Case Report and Review of the Literature.

Calvert H, Kapurubandara S, Nikam Y, Sharma R, Achan A.

Case Rep Obstet Gynecol. 2018 Apr 29;2018:8579026. doi: 10.1155/2018/8579026. eCollection 2018.

6.

Barriers to Shared Use of Indoor and Outdoor Facilities at US Elementary Schools.

Turner L, Calvert HG, Chaloupka FJ.

J Sch Health. 2018 May;88(5):379-387. doi: 10.1111/josh.12621.

PMID:
29609211
7.

Classroom-Based Physical Activity: Minimizing Disparities in School-Day Physical Activity Among Elementary School Students.

Calvert HG, Mahar MT, Flay B, Turner L.

J Phys Act Health. 2018 Mar 1;15(3):161-168. doi: 10.1123/jpah.2017-0323. Epub 2017 Nov 25.

PMID:
28872390
8.

AN AUDIT TO ASSESS THE TIMINGS OF TTAS AND INPATIENT ORDERS IN PAEDIATRICS; FROM WRITING, TO SCREENING, TO DISPENSING, AND TO LEAVING DISPENSARY.

Hale A, Christiansen N, Calvert H.

Arch Dis Child. 2016 Sep;101(9):e2. doi: 10.1136/archdischild-2016-311535.67.

PMID:
27540250
9.

Acute high-intensity exercise-induced cognitive enhancement and brain-derived neurotrophic factor in young, healthy adults.

Hwang J, Brothers RM, Castelli DM, Glowacki EM, Chen YT, Salinas MM, Kim J, Jung Y, Calvert HG.

Neurosci Lett. 2016 Sep 6;630:247-253. doi: 10.1016/j.neulet.2016.07.033. Epub 2016 Jul 20.

PMID:
27450438
10.

HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.

Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S, Vergote I, Calvert H, Jacobs IJ, Widschwendter M.

Genome Med. 2015 Oct 24;7:108. doi: 10.1186/s13073-015-0233-4.

11.

Does mother know best?

Calvert H.

Community Pract. 2015 Mar;88(3):42-3. No abstract available.

PMID:
25812242
12.

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.

Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Öhman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P.

Lancet Oncol. 2015 Apr;16(4):447-56. doi: 10.1016/S1470-2045(15)70056-2. Epub 2015 Mar 20. Erratum in: Lancet Oncol. 2015 May;16(5):e199.

PMID:
25800891
13.

'Breast isn't best, it's just normal'.

Calvert H.

Nurs Child Young People. 2014 Dec;26(10):15. doi: 10.7748/ncyp.26.10.15.s23.

PMID:
25487398
14.

VII. The history of physical activity and academic performance research: informing the future.

Castelli DM, Centeio EE, Hwang J, Barcelona JM, Glowacki EM, Calvert HG, Nicksic HM.

Monogr Soc Res Child Dev. 2014 Dec;79(4):119-48. doi: 10.1111/mono.12133. Review.

PMID:
25387418
15.

Impact of trained champions of comprehensive school physical activity programs on school physical activity offerings, youth physical activity and sedentary behaviors.

Carson RL, Castelli DM, Pulling Kuhn AC, Moore JB, Beets MW, Beighle A, Aija R, Calvert HG, Glowacki EM.

Prev Med. 2014 Dec;69 Suppl 1:S12-9. doi: 10.1016/j.ypmed.2014.08.025. Epub 2014 Aug 23.

PMID:
25158209
16.

Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.

Calvert H, Twelves C, Ranson M, Plummer R, Fettner S, Pantze M, Ling J, Hamilton M, Lum BL, Rakhit A.

Anticancer Drugs. 2014 Aug;25(7):832-40. doi: 10.1097/CAD.0000000000000099.

PMID:
24637575
17.

Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.

Plummer R, Lorigan P, Brown E, Zaucha R, Moiseyenko V, Demidov L, Soriano V, Chmielowska E, Andrés R, Kudryavtseva G, Kahatt C, Szyldergemajn S, Extremera S, de Miguel B, Cullell-Young M, Calvert H.

Br J Cancer. 2013 Sep 17;109(6):1451-9. doi: 10.1038/bjc.2013.477. Epub 2013 Aug 29.

18.

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.

Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, Abbattista A, Gallo J, Calvert H.

Cancer Chemother Pharmacol. 2013 May;71(5):1191-9. doi: 10.1007/s00280-013-2113-1. Epub 2013 Feb 20.

PMID:
23423489
19.

Vitamin D and asthma.

Brown SD, Calvert HH, Fitzpatrick AM.

Dermatoendocrinol. 2012 Apr 1;4(2):137-45. doi: 10.4161/derm.20434.

20.

Synthetic lethality to overcome cancer drug resistance.

Porcelli L, Quatrale AE, Mantuano P, Silvestris N, Brunetti AE, Calvert H, Paradiso A, Azzariti A.

Curr Med Chem. 2012;19(23):3858-73. Review.

PMID:
22788762
21.

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.

Massard C, Margetts J, Amellal N, Drew Y, Bahleda R, Stephens P, Armand JP, Calvert H, Soria JC, Coronado C, Kahatt C, Alfaro V, Siguero M, Fernández-Teruel C, Plummer R.

Invest New Drugs. 2013 Jun;31(3):623-30. doi: 10.1007/s10637-012-9843-5. Epub 2012 Jun 12. Erratum in: Invest New Drugs. 2013 Jun;31(3):799. Stevens, Peter [corrected to Stephens, Peter].

PMID:
22688291
22.

Targeted agents: how to select the winners in preclinical and early clinical studies?

Goodwin R, Giaccone G, Calvert H, Lobbezoo M, Eisenhauer EA.

Eur J Cancer. 2012 Jan;48(2):170-8. doi: 10.1016/j.ejca.2011.09.024. Epub 2011 Nov 15. Review.

PMID:
22093946
23.

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.

Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, Lewis S, Lock V, Yule M, Lyons J, Calvert H, Judson I.

Ann Oncol. 2012 May;23(5):1307-13. doi: 10.1093/annonc/mdr451. Epub 2011 Oct 19.

PMID:
22015452
24.

Medical students in developing countries.

Merlin J, Morrison G, Gluckman S, Lipschik G, Linkin DR, Lyon S, O'Grady E, Calvert H, Friedman H.

J Gen Intern Med. 2011 Aug;26(8):833. doi: 10.1007/s11606-011-1744-3. No abstract available.

25.

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.

Rustin G, Reed N, Jayson GC, Ledermann JA, Adams M, Perren T, Poole C, Lind M, Persic M, Essapen S, Gore M, Calvert H, Stredder C, Wagner A, Giurescu M, Kaye S.

Ann Oncol. 2011 Nov;22(11):2411-6. doi: 10.1093/annonc/mdq780. Epub 2011 Mar 3.

PMID:
21372124
26.

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.

Mahadevan D, Plummer R, Squires MS, Rensvold D, Kurtin S, Pretzinger C, Dragovich T, Adams J, Lock V, Smith DM, Von Hoff D, Calvert H.

Ann Oncol. 2011 Sep;22(9):2137-43. doi: 10.1093/annonc/mdq734. Epub 2011 Feb 16.

PMID:
21325451
27.

The clinical development of inhibitors of poly(ADP-ribose) polymerase.

Calvert H, Azzariti A.

Ann Oncol. 2011 Jan;22 Suppl 1:i53-9. doi: 10.1093/annonc/mdq667. Review.

PMID:
21285153
28.

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours.

Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, Sludden J, Tilby MJ, Eatock M, Pearson DG, Ottley CJ, Matsumura Y, Kataoka K, Nishiya T.

Br J Cancer. 2011 Feb 15;104(4):593-8. doi: 10.1038/bjc.2011.6. Epub 2011 Feb 1.

29.

Blood and body fluid exposures among US medical students in Botswana.

Merlin JS, Morrison G, Gluckman S, Lipschik G, Linkin DR, Lyon S, O'Grady E, Calvert H, Friedman H.

J Gen Intern Med. 2011 May;26(5):561-4. doi: 10.1007/s11606-010-1586-4. Epub 2010 Nov 30.

30.

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.

Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R.

J Clin Oncol. 2010 Sep 1;28(25):3965-72. doi: 10.1200/JCO.2009.26.7278. Epub 2010 Aug 2.

PMID:
20679611
31.

Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.

Forster MD, Saijo N, Seymour L, Calvert H.

Clin Cancer Res. 2010 Mar 15;16(6):1737-44. doi: 10.1158/1078-0432.CCR-09-2228. Epub 2010 Mar 9. Erratum in: Clin Cancer Res. 2010 Jul 15;16(14):3807.

32.

A monoclonal antibody for detection of folylpolyglutamate synthetase in paraffin embedded tissues.

Quinn AE, Pinkney M, Piggott NH, Calvert H, Milton ID, Lunec J.

Hybridoma (Larchmt). 2009 Dec;28(6):415-21. doi: 10.1089/hyb.2009.0040.

PMID:
20025500
33.

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JH, Shapiro GI.

Ann Oncol. 2010 Apr;21(4):884-94. doi: 10.1093/annonc/mdp377. Epub 2009 Oct 13.

34.

Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.

Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Blackie R, Schatzlein A, Jodrell D, Bissett D, Calvert H, Lind M, Robbins A, Burtles S, Duncan R, Cassidy J.

Int J Oncol. 2009 Jun;34(6):1629-36.

PMID:
19424581
35.

Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.

Plummer R, Vidal L, Griffin M, Lesley M, de Bono J, Coulthard S, Sludden J, Siu LL, Chen EX, Oza AM, Reid GK, McLeod AR, Besterman JM, Lee C, Judson I, Calvert H, Boddy AV.

Clin Cancer Res. 2009 May 1;15(9):3177-83. doi: 10.1158/1078-0432.CCR-08-2859. Epub 2009 Apr 21.

36.

A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.

Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J.

Eur J Cancer. 2009 May;45(8):1415-23. doi: 10.1016/j.ejca.2008.12.013. Epub 2009 Jan 23.

PMID:
19168349
37.

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H.

Clin Cancer Res. 2008 Dec 1;14(23):7917-23. doi: 10.1158/1078-0432.CCR-08-1223.

38.

The potential of PARP inhibitors in genetic breast and ovarian cancers.

Drew Y, Calvert H.

Ann N Y Acad Sci. 2008 Sep;1138:136-45. doi: 10.1196/annals.1414.020.

PMID:
18837894
39.

Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).

Graham JS, Plummer R, McCoy C, Kowal K, Wiesinger H, Detjen K, Calvert H, Wiedenmann B, Cassidy J.

Eur J Cancer. 2008 Oct;44(15):2162-8. doi: 10.1016/j.ejca.2008.06.006. Epub 2008 Jul 22.

PMID:
18653327
40.

Mechanisms of chemoresistance to alkylating agents in malignant glioma.

Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W.

Clin Cancer Res. 2008 May 15;14(10):2900-8. doi: 10.1158/1078-0432.CCR-07-1719. Review.

41.

A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues.

Smith AE, Pinkney M, Piggott NH, Calvert H, Milton ID, Lunec J.

Hybridoma (Larchmt). 2007 Oct;26(5):281-8.

PMID:
17979543
42.

Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.

Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Féty R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH.

Clin Cancer Res. 2007 Nov 1;13(21):6410-8.

43.

Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy.

Plummer ER, Calvert H.

Clin Cancer Res. 2007 Nov 1;13(21):6252-6. Review.

44.

Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.

Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert H, de Bono J.

Clin Cancer Res. 2007 Oct 15;13(20):6187-94.

45.

Extracellular heat shock protein 70 has novel functional effects on sea urchin eggs and coelomocytes.

Browne CL, Swan JB, Rankin EE, Calvert H, Griffiths S, Tytell M.

J Exp Biol. 2007 Apr;210(Pt 7):1275-87.

46.

Efficacy of botulinum toxin in chronic anal fissure.

Simms HN, McCallion K, Wallace W, Campbell WJ, Calvert H, Moorehead RJ.

Ir J Med Sci. 2004 Oct-Dec;173(4):188-90.

PMID:
16323610
47.
48.

Surgical treatment of hepatic hydatid cyst.

Mcfall B, Yousaf M, Calvert H, Diamond T, Epanomeritakis M.

Int J Clin Pract. 2004 May;58(5):479-82. Review.

PMID:
15206505
49.

Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.

Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C, Fargeot P, Bottomley A; EORTC-BCG-IDBBC-NDDG.

Eur J Cancer. 2004 May;40(7):1021-30.

PMID:
15093577
50.

Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.

Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z, Newell DR.

Clin Cancer Res. 2004 Feb 1;10(3):881-9.

Supplemental Content

Loading ...
Support Center